Physician profile
Carson Womack
NPI 1942839568
$4,488.63
in general payments reported to CMS, 2019-2025
30 companies · $4,437 in 2025
The $4,437 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.38 · 2023: $30.59 · 2025: $4,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,426 · Travel and Lodging: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,425.79 |
| Travel and Lodging | $1,041.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,866.12 | 2025 | Minimed 780g |
| Abbott Laboratories | $345.31 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $278.32 | 2025 | |
| Mannkind Corporation | $237.82 | 2025 | |
| Lilly USA, LLC | $229.37 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $204.02 | 2025 | Ozempic, Wegovy, Rybelsus |
| Radius Health, INC. | $135.81 | 2025 | Tymlos |
| Madrigal Pharmaceuticals | $131.79 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $104.03 | 2025 | |
| Corcept Therapeutics | $100.49 | 2025 | Korlym |
| Cequr Corporation | $88.28 | 2025 | Cequr Simplicity |
| Amgen INC. | $83.55 | 2025 | Tepezza, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.08 | 2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $71.13 | 2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $66.32 | 2025 | Yorvipath, Skytrofa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $59.88 | 2025 | Mycapssa, Juxtapid |
| Neurocrine Biosciences, INC. | $56.07 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $48.94 | 2025 | |
| Recordati_rare_diseases_inc. | $40.68 | 2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $37.80 | 2025 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $34.17 | 2025 | Tirosint, Licart, Flector |
| Rhythm Pharmaceuticals, INC. | $33.10 | 2025 | Imcivree |
| Dexcom, INC. | $22.53 | 2025 | Dexcom G6 Transmitter |
| Soleno Therapeutics, INC. | $21.50 | 2025 | Vykat Xr |
| Bayer Healthcare Pharmaceuticals INC. | $21.38 | 2022 | |
| Averitas Pharma INC. | $20.29 | 2025 | Qutenza |
| Kyowa Kirin, INC. | $18.89 | 2025 | |
| Tolmar, INC. | $17.19 | 2025 | Jatenzo |
| Abbvie INC. | $16.28 | 2023 | Teflaro |
| Ionis Pharmaceuticals, INC. | $15.49 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.